A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

NCT01169298 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult T-cell Leukemia-Lymphoma
Peripheral T-cell Lymphoma

Interventions

DRUG: Lenalidomide

Sponsor

Celgene